𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Pegylated liposomal doxorubicin in combination with dexamethasone and bortezomib (VMD) or lenalidomide (RMD) in multiple myeloma pretreated patients

✍ Scribed by Gabriele Buda; Enrico Orciuolo; Sara Galimberti; Matteo Pelosini; Mario Petrini

Publisher
Springer
Year
2010
Tongue
English
Weight
66 KB
Volume
90
Category
Article
ISSN
0939-5555

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Combined pegylated liposomal doxorubicin
Combined pegylated liposomal doxorubicin and bortezomib is highly effective in patients with recurrent or refractory multiple myeloma who received prior thalidomide/lenalidomide therapy
✍ Pieter Sonneveld; Roman Hajek; Arnon Nagler; Andrew Spencer; Joan BladΓ©; Tadeusz πŸ“‚ Article πŸ“… 2008 πŸ› John Wiley and Sons 🌐 English βš– 137 KB

## Abstract ## BACKGROUND Recently, the authors reported improved time to disease progression (TTP) with a combination of pegylated liposomal doxorubicin (PLD) and bortezomib compared with bortezomib alone in a phase 3 randomized trial in patients with recurrent/refractory multiple myeloma (MM). I

A Phase II trial of pegylated liposomal
A Phase II trial of pegylated liposomal doxorubicin, vincristine, and reduced-dose dexamethasone combination therapy in newly diagnosed multiple myeloma patients
✍ Mohamad A. Hussein; Laura Wood; Eric Hsi; Gordan Srkalovic; MaryAnn Karam; Paul πŸ“‚ Article πŸ“… 2002 πŸ› John Wiley and Sons 🌐 English βš– 91 KB πŸ‘ 1 views

## Abstract ## BACKGROUND Patients with multiple myeloma (MM) have increased bone marrow angiogenesis, a low plasma cell labeling index, and multidrug resistance (the primary cause of chemotherapy failure). MM patients receiving the vincristine, doxorubicin, and dexamethasone (VAD) regimen develop